Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $90.72.

  • Lifecore Biomedical, Inc. \De\'s Debt to Equity rose 91037.84% to $90.72 in Q2 2025 from the same period last year, while for May 2025 it was $90.72, marking a year-over-year increase of 91037.84%. This contributed to the annual value of $90.72 for FY2025, which is 91037.84% up from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s Debt to Equity stood at $90.72, which was up 91037.84% from $51.89 recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Debt to Equity peaked at $90.72 during Q2 2025, and registered a low of -$27.0 during Q3 2024.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median Debt to Equity value was $1.19 (recorded in 2022), while the average stood at $10.4.
  • Examining YoY changes over the last 5 years, Lifecore Biomedical, Inc. \De\'s Debt to Equity showed a top increase of 459816.71% in 2023 and a maximum decrease of 189404.74% in 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Debt to Equity (Quarter) stood at $1.07 in 2021, then skyrocketed by 30.08% to $1.39 in 2022, then surged by 4598.17% to $65.35 in 2023, then tumbled by 88.98% to $7.2 in 2024, then skyrocketed by 1159.19% to $90.72 in 2025.
  • Its Debt to Equity was $90.72 in Q2 2025, compared to $51.89 in Q1 2025 and $7.2 in Q4 2024.